Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer.
Background: Triple‐negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II‐III TNBC. This study evaluates the impact of NAIC on surgical outcomes versus neoadjuvant chemoth...
| Publicado en: | Breast Journal Vol. 2026; pp. 1 - 10 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
7/17/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195474718&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195474718 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1075122X ET6 jtl: Breast Journal issn: 1075122X maglogo: Y pubinfo: dt: 7/17/2026 vid: 2026 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 195474718 195474718 195474718 10.1155/tbj/5534220 195474718 ppf: 1 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer. aug: au: Khadrouche, Tamasine Morisseau, Mathilde Selmes, Gabrielle Vaysse, Charlotte Franchet, Camille Massabeau, Carole Ung, Mony Maio, Eleonora De Lacaze, Jean-Louis Jouve, Eva Wani, Imtiaz affil: Department of Surgical Oncology,, Claudius Regaud Institute–IUCT Oncopole,, Toulouse, France sug: subj: Breast Neoplasms Surgery Breast Neoplasms Drug Therapy Neoplasm Staging Postoperative Complications Immunotherapy Methods Neoadjuvant Therapy Chemotherapy, Cancer Breast Neoplasms Radiotherapy Treatment Outcomes Evaluation Time Factors Evaluation Antineoplastic Agents Therapeutic Use Human Female Adult Middle Age Aged Retrospective Design Prospective Studies Electronic Health Records Record Review Body Mass Index Comparative Studies Chi Square Test Fisher's Exact Test Kruskal-Wallis Test Multivariate Statistics Logistic Regression Odds Ratio Confidence Intervals Data Analysis Software Clinical Assessment Tools Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Female ab: Background: Triple‐negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II‐III TNBC. This study evaluates the impact of NAIC on surgical outcomes versus neoadjuvant chemotherapy (NAC). Methods: A retrospective cohort study included 117 Stage II‐III TNBC patients treated with NAIC or NAC (October 2019–May 2023). Surgical complications, time to surgery, time to radiotherapy, and pathologic response were assessed. Complications were classified using the Clavien–Dindo scale; immune‐related adverse events (irAEs) followed the 2017 CTCAE criteria. Results: Among 117 patients, 59 received NAIC and 58 NAC. Chemotherapy‐related adverse events were similar (NAIC: 78.0%, NAC: 75.9%). irAEs occurred in 50.8% of NAIC patients, with 8.5% experiencing severe irAEs. Surgical complications were more frequent in NAIC (27.1%) than NAC (17.2%), though not statistically significant; seroma was the most common. Delays > 12 weeks in initiating radiotherapy were more frequent in NAIC (10.7%) than NAC (0%). Conclusion: NAIC did not significantly increase postoperative complications compared to NAC. However, irAEs and potential treatment delays warrant careful management. Despite these risks, NAIC remains a viable option for early TNBC with manageable surgical outcomes. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|